Analyst Reco. IDEAYA Biosciences, Inc.

Equities

IDYA

US45166A1025

Real-time Estimate Cboe BZX Other stock markets 02:19:32 2024-05-28 pm EDT			5-day change	1st Jan Change
37.87 ^USD	+0.42%		-7.87%	+6.17%

12:00pm	IDEAYA Biosciences, Inc. Appoints Daniel A. Simon as Chief Business Officer, Effective August 2024	CI
May. 16	Ideaya Biosciences Insider Sold Shares Worth $7,397,291, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Ideaya Biosciences Insider Sold Shares Worth $7,397,291, According to a Recent SEC Filing	May. 16	MT
Oppenheimer Adjusts IDEAYA Biosciences Price Target to $53 From $50, Maintains Outperform Rating	May. 08	MT
Citigroup Raises IDEAYA Biosciences' Price Target to $60 From $40, Maintains Buy Rating	Mar. 21	MT
BTIG Starts Coverage on IDEAYA Biosciences With Buy Rating, $55 Price Target	Mar. 08	MT
RBC Raises Price Target on IDEAYA Biosciences to $53 From $43 on 'Clarity & Confidence on Daro's Potential,' Keeps Outperform Rating, Speculative Risk	Feb. 21	MT
Wedbush Raises IDEAYA Biosciences' PT to $52 From $46, Updates Model to Include Recent Financings; Keeps Outperform Rating	Feb. 20	MT
Goldman Sachs Adjusts Price Target on IDEAYA Biosciences to $53 From $36, Maintains Buy Rating	Jan. 25	MT
Wedbush Raises Price Target on IDEAYA Biosciences to $46 From $43, Maintains Outperform Rating	Jan. 16	MT
RBC Adjusts IDEAYA Biosciences' Price Target to $43 From $36, Keeps Outperform Rating	Jan. 10	MT
JPMorgan Raises IDEAYA Biosciences' Price Target to $35 From $32, Maintains Overweight Rating	23-10-24	MT
RBC Raises Price Target on IDEAYA Biosciences to $36 From $32, Keeps Outperform Rating, Speculative Risk Qualifier	23-10-24	MT
Wedbush Lifts Ideaya Biosciences' Price Target to $43 From $40 After Phase 1 Study of Novel PARG Inhibitor IDE16 Early Results, Keeps Outperform Rating	23-09-12	MT
Goldman Sachs Adjusts IDEAYA Biosciences' Price Target to $37 From $31, Keeps Buy Rating	23-09-12	MT
Wedbush Lifts Ideaya Biosciences' Price Target to $43 From $40, Keeps Outperform Rating	23-09-12	MT
JPMorgan Chase Raises Price Target on IDEAYA Biosciences to $32 From $28, Maintains Overweight Rating	23-08-17	MT
Oppenheimer Adjusts IDEAYA Biosciences Price Target to $35 From $30, Maintains Outperform Rating	23-08-11	MT
RBC Raises Price Target on IDEAYA Biosciences to $32 From $30, Maintains Outperform Rating, Speculative Risk Qualifier	23-08-11	MT
Wedbush Raises IDEAYA Biosciences' PT to $40 From $35 on Increased Confidence in IDE397/AMG 193 Combination, Keeps Outperform Rating	23-08-11	MT
SVB Securities Initiates IDEAYA Biosciences With Outperform Rating, $33 Price Target	23-08-08	MT
Wedbush Trims Foghorn Therapeutics Price Target to $13 From $14, Maintains Outperform Rating	23-06-28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. IDEAYA Biosciences, Inc.

Equities

IDYA

US45166A1025

Analyst Reco.

Filters